opfolda miglustat 65 mg

1 INDICATIONS AND USAGE OPFOLDA is indicated, in combination with Pombiliti, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). OPFOLDA is an enzyme stabilizer indicated, in combination with Pombiliti, a hydrolytic lysosomal glycogen-specific enzyme, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). ( 1 )

amicus therapeutics us, llc

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] fatigue` `[4] off label use` `[5] diarrhoea` `[6] dyspnoea` `[7] pain` `[8] headache` `[9] vomiting` `[10] dizziness`

1 year ago

CAPSULE GREY AT2221

16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied OPFOLDA (

MIGLUSTAT) capsules are supplied as 65 mg, white opaque hard gelatin capsules with a grey opaque cap with “AT2221” printed in black on the body, and are available in bottles with child resistant caps. See Table 5 for the available OPFOLDA packages. Table 5. OPFOLDA Packages Package Size NDC 4 count bottle 71904-300-01 24 count bottle 71904-300-02 100 count bottle 71904-300-03 Storage and Handling Store at 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C to 30°C (59°F to 86°F), [see USP Controlled Room Temperature]. Store in the original container to protect from light.

More pills like CAPSULE AT2221

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

opfolda miglustat 65 mg

FDA Reported Adverse Reactions [1] drug ineffective [2] nausea [3] fatigue [4] off label use [5] diarrhoea [6] dyspnoea [7] pain [8] headache [9] vomiting [10] dizziness

CAPSULE GREY AT2221

More pills like CAPSULE AT2221

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] nausea` `[3] fatigue` `[4] off label use` `[5] diarrhoea` `[6] dyspnoea` `[7] pain` `[8] headache` `[9] vomiting` `[10] dizziness`